首页> 外文期刊>World Journal of Gastroenterology >Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer
【24h】

Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer

机译:Tropomyosin相关激酶B /脑源性神经营养因子信号通路可作为结直肠癌的潜在治疗靶标

获取原文
           

摘要

Colorectal cancer (CRC) is the second most common cause of cancer-related death in western countries. Approximately one-quarter of newly diagnosed patients for CRC have metastases, and a further 40%-50% experience disease recurrence or develop metastases after all standard therapies. Therefore, understanding the molecular mechanisms involved in the progression of CRC and subsequently developing novel therapeutic targets is crucial to improve management of CRC and patients’ long-term survival. Several tyrosine kinase receptors have been implicated in CRC development, progression and metastasis, including epidermal growth factor receptor (EGFR) and vascular EGFR. Recently, tropomyosin-related kinase B (TrkB), a tyrosine kinase receptor, has been reported in CRC and found to clearly exert several biological and clinical features, such as tumor cell growth and survival in vitro and in vivo, metastasis formation and poor prognosis. Here we review the significance of TrkB and its ligand brain derived-neurotrophic factor in CRC. We focus on their expression in CRC tumor samples, and their functional roles in CRC cell lines and in in vivo models. Finally we discuss therapeutic approaches that can lead to the development of novel therapeutic agents for treating TrkB-expressing CRC tumors.
机译:结直肠癌(CRC)是西方国家第二大最常见的癌症相关死亡原因。在所有新疗法中,大约有四分之一的新近被诊断患有CRC的患者有转移,另有40%-50%的患者经历了疾病复发或发生了转移。因此,了解CRC进展中涉及的分子机制并随后开发新的治疗靶标对于改善CRC的管理和患者的长期生存至关重要。几种酪氨酸激酶受体与CRC的发生,发展和转移有关,包括表皮生长因子受体(EGFR)和血管EGFR。最近,CRC中已报道了酪氨酸激酶受体原肌球蛋白相关激酶B(TrkB),并发现其具有多种生物学和临床特征,例如肿瘤细胞在体内外的生长和存活,转移形成和预后不良。 。在这里,我们回顾了TrkB及其配体脑源性神经营养因子在CRC中的意义。我们专注于它们在CRC肿瘤样品中的表达,以及它们在CRC细胞系和体内模型中的功能。最后,我们讨论了可导致开发新型表达TrkB CRC肿瘤的治疗剂的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号